

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

In previous multiple myeloma evaluations, stakeholders have noted that the condition is common in men, older people, and people from Black African and Caribbean ethnic groups. The committee will consider all possible equality issues at the time of the evaluation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

The following stakeholders have been identified and been added to the stakeholder list:

- African Caribbean Leukaemia Trust

Approved by Associate Director (name):

...Lorna Dunning.....

Date: 06/05/26